NASDAQ OMX GlobeNewswire

Quit smoking without nicotine: Pharmathen Hellas S.A. to distribute Acetium® lozenge in Greece

Jaa
Quit smoking without nicotine: Pharmathen Hellas S.A. to distribute Acetium® lozenge in Greece

Biohit Oyj Press release, January 30, 2018 at 12.45 p.m. local time (EET)

Biohit Oyj and Pharmathen Hellas S.A. have signed an agreement for the distribution of the smoking cessation product Acetium lozenge in Greece. The contract has been signed for three years with a continuation option. The first deliveries of the product will be in early 2018.

The new Acetium lozenge is an effective and safe product that helps quit smoking without nicotine and it has no side effects. Acetium lozenge eliminates cigarette smoke-derived carcinogenic acetaldehyde in the saliva during smoking. According to the clinical trial, Acetium lozenge helps to quit smoking (1-3).

Executive Eleni Katsou, Pharmathen Hellas S.A.: ”Greece is one of the leading countries in Europe as measured by the proportion of active smokers: more than 30% of all 15-year-old people are current smokers. In addition, almost two-thirds of the people are regularly exposed to passive smoking. Acetium lozenge as an entirely novel method in smoking intervention fits very well with the mission of our company, and we have a long-term business expertise in the market of health products in particular.”

CEO Semi Korpela, Biohit Oyj: ”With this agreement, Pharmathen Hellas S.A. obtains the rights to distribute Acetium lozenge in Greece. In a country like Greece, where smoking-related diseases represent a major national health burden, Acetium lozenge offers a side effect-free and safe option to abandon this unhealthy addiction.”

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

1. Syrjänen K, Eronen K, Hendolin P, Paloheimo L, Eklund C, Bäckström A, Suovaniemi O. Slow-release L-cysteine (Acetium®) lozenge is an effective new method in smoking cessation. A randomized, double-blind, placebo-controlled intervention. Anticancer Res 2017;37:3639-3648.

2. https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=785626&lang=en

3. http://www.biohithealthcare.com/resource/files/media/other/acetium-lozenge-quitsmoking-brochure-en-for-pr.pdf


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


Pharmathen in brief

Pharmathen’s core business is the development of complex generic products, advanced pharmaceutical technologies and platforms.  As of September 2017, the company’s total headcount reached 1061 highly qualified professionals. The company is committed to scientific excellence and continuous R&D investments, aiming to enhance its product portfolio, provide innovative solutions and services to customers and patients, whilst maintaining and securing a strong financial performance.

Tietoja julkaisijasta

NASDAQ OMX GlobeNewswire
NASDAQ OMX GlobeNewswire
Fabianinkatu 14
00130 HELSINKI

+45 33 77 03 77http://globenewswire.com
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta NASDAQ OMX GlobeNewswire

GlobeNewswire Test Release19.5.2018 07:00Tiedote

GlobeNewswire Test Release LOS ANGELES, May 18, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

Eroon tupakasta ilman nikotiinia: Pharmathen Hellas S.A. Acetium® imeskelytabletin jakelijaksi Kreikassa30.1.2018 11:45Tiedote

Eroon tupakasta ilman nikotiinia: Pharmathen Hellas S.A. Acetium® imeskelytabletin jakelijaksi Kreikassa Biohit Oyj Lehdistötiedote 30.1.2018 12:45 paikallista aikaa (EEST) Biohit Oyj ja Pharmathen Hellas S.A. ovat allekirjoittaneet sopimuksen tupakoinnin lopettamiseen tarkoitetun Acetium imeskelytabletin jakelusta Kreikassa. Sopimus on solmittu kolmeksi vuodeksi jatko-optiolla. Ensimmäinen erä tuotetta toimitetaan alkuvuodesta 2018. Uusi Acetium imeskelytabletti on tehokas ja turvallinen tuote, joka auttaa eroon tupakasta ilman riippuvuutta aiheuttavaa nikotiinia ja sillä ei ole sivuvaikutuksia. Acetium imeskelytablettia käytetään tupakoinnin aikana ja se poistaa tehokkaasti tupakansavusta sylkeen liukenevaa karsinogeenistä asetaldehydiä. Kliinisen tutkimuksen mukaan Acetium imeskelytabletin käyttö auttaa tupakoinnin lopettamisessa (1-3). Johtaja Eleni Katsou, Pharmathen Hellas S.A.: ”Kreikka on Euroopan johtavia maita tupakoitsijoiden määrällä mitattuna; reilut 30% 15 vuotta täyttäne

Soprano Oyj: Soprano uudistaa organisaationsa ja selvittää joukkorahoitusta30.11.2016 09:00Tiedote

Soprano Oyj pörssitiedote 30.11.2016 klo 9.00 Soprano uudistaa organisaationsa ja selvittää joukkorahoitusta Kehitysyhtiö Sopranon täysin omistamat koulutusyhtiöt, Informator Tieturi Group ja Management Institute of Finland MIF, raportoidaan 1.1.2017 alkaen erillisinä segmentteinä läpinäkyvyyden lisäämiseksi ja kasvun vauhdittamiseksi. Emoyhtiön kanssa samassa segmentissä raportoidaan jatkossa Sopranon osakkuusyhtiöt Brain Alliance Oy sekä Ambientia E-commerce Oy. Sopranon Ruotsin tytäryhtiön Informator Utbildning Ab:n toimitusjohtaja Emil Robertsson on nimitetty konsernin suomalaisen tytäryhtiön Tieturi Oy:n toimitusjohtajaksi ja uuden Informator Tieturi Group –segmentin johtajaksi. Robertsson jatkaa myös Informatorin toimitusjohtajana. Soprano Oyj:n toimitusjohtaja Kaisa Vikkula jatkaa myös Management Institute of Finland MIF Oy:n toimitusjohtajana sekä segmentistä vastaavana johtajana. Segmentin muodostavat Johtamistaidon Opisto, Infor ja MIF Tutkinnot –liiketoiminnot Suomessa ja Pi

BroadSoft, Inc.: BroadSoft Hub Adds Contextual Intelligence to Communications for Greater Workforce Productivity14.11.2016 09:00Tiedote

GAITHERSBURG, Md., 2016-11-14 08:00 CET (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT), a global unified communication software as a service (UCaaS) leader, today announced the launch of BroadSoft Hub, a new enterprise-grade cloud service integrating real-time communications with cloud applications and contextual intelligence for more productive communications and greater mobility. Hub is powering the future of work by providing BroadSoft Business users with immediate access to relevant information for every conversation - wherever they are, on whatever device. Workforce productivity suffers when the relationship between multiple business applications and real-time communications are disjointed. According to a 2014 HubSpot research report, an average of 31 hours per month is spent in unproductive meetings, with much of this time taken up searching through information scattered across locations, devices and applications1. As a result, business processes and workflows often become fra

Karolinska Development AB: Change of number of shares and votes in Karolinska Development30.9.2016 10:00Tiedote

Today, the last trading day of the month, there are in total 53,464,998 shares outstanding which in total have 66,992,880 votes in Karolinska Development. Of these, 1,503,098 are series A shares with 15,030,980 votes and 51,961,900 B shares with one vote each. For further information, please contact: Jim Van heusden, CEO, Karolinska Development AB Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com Christian Tange, CFO, Karolinska Development AB Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson Phone: +44 20 7638 9571, e-mail: KDev@citigatedr.co.uk TO THE EDITORS About Karolinska Development AB Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients’ lives and provide an attractive return on investme

Euroloan Group Oyj: Euroloan Group Plc Interim Report 1.4.-30.6.201611.8.2016 09:00Tiedote

Helsinki, Finland, 2016-08-11 08:00 CEST (GLOBE NEWSWIRE) -- The quarterly income of Euroloan Group Plc reached EUR 5,2 million, exceeding the EUR 5 million level for the first time in the Group’s history. Quarterly income increased by 54% compared with the average quarterly income in 2015. Profitability continues to increase as EBIT grew by 78% to EUR 3,5 million compared to Q2/2015 and net profit increased by 250% to EUR 2,8 million. Compared to the 2015 quarterly average, EBIT increased by 110% and net profit by 394%. The Group’s solidity continued to improve, as the equity ratio has almost doubled to 60% from 31% in Q2/2015, with total equity now at EUR 28,6 million. The total balance is reduced due to a funding arrangement where receivables are sold to a third party. Key Figures Q2 2016 Q1 2016 Q2 2015 Q1 2015 2015 Balance (million EUR) 48,1 49,9 57,5 53,3 49,5 Total income (million EUR) 5,2 4,0 4,3 2,6 13,4 EBIT (million EUR) 3,5 2,0 2,0 0,5 6,6 EBIT Growth 78 % 311 % 206%* -22 %

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme